Statement of Changes in Beneficial Ownership (4)
06 October 2022 - 7:16AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Eckelman Brendan P. |
2. Issuer Name and Ticker or Trading Symbol
Inhibrx, Inc.
[
INBX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Officer |
(Last)
(First)
(Middle)
C/O INHIBRX, INC., 11025 NORTH TORREY PINES ROAD, SUITE 200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/4/2022 |
(Street)
LA JOLLA, CA 92037
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 10/4/2022 | | S(1) | | 1448 | D | $24.6688 (2) | 2274105 | I | By the Eckelman Living Trust dated February 5, 2014 (3) |
Common Stock | 10/4/2022 | | S(1) | | 6207 | D | $26.0614 (4) | 2267898 | I | By the Eckelman Living Trust dated February 5, 2014 (3) |
Common Stock | 10/4/2022 | | S(1) | | 11136 | D | $26.7764 (5) | 2256762 | I | By the Eckelman Living Trust dated February 5, 2014 (3) |
Common Stock | 10/4/2022 | | S(1) | | 4262 | D | $27.7566 (6) | 2252500 | I | By the Eckelman Living Trust dated February 5, 2014 (3) |
Common Stock | 10/4/2022 | | S(1) | | 5954 | D | $28.9713 (7) | 2246546 | I | By the Eckelman Living Trust dated February 5, 2014 (3) |
Common Stock | 10/4/2022 | | S(1) | | 10893 | D | $29.6798 (8) | 2235653 | I | By the Eckelman Living Trust dated February 5, 2014 (3) |
Common Stock | 10/4/2022 | | S(1) | | 100 | D | $30.52 | 2235553 | I | By the Eckelman Living Trust dated February 5, 2014 (3) |
Common Stock | | | | | | | | 160000 | I | By trust (9) |
Common Stock | | | | | | | | 160000 | I | By trust (10) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Eckelman Living Trust dated February 5, 2014. |
(2) | The shares were sold in multiple transactions at prices ranging from $24.23 to $25.20, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
(3) | These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014. |
(4) | The shares were sold in multiple transactions at prices ranging from $25.35 to $26.33, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
(5) | The shares were sold in multiple transactions at prices ranging from $26.35 to $27.32, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
(6) | The shares were sold in multiple transactions at prices ranging from $27.35 to $28.33, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
(7) | The shares were sold in multiple transactions at prices ranging from $28.35 to $29.34, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
(8) | The shares were sold in multiple transactions at prices ranging from $29.40 to $30.23, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
(9) | These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust. |
(10) | These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Eckelman Brendan P. C/O INHIBRX, INC. 11025 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037 |
|
| Chief Scientific Officer |
|
Eckelman Living Trust Dated February 5, 2014 C/O INHIBRX, INC. 11025 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037 |
| X |
|
|
Signatures
|
/s/ Kelly D. Deck, attorney-in-fact | | 10/5/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Inhibrx Biosciences (NASDAQ:INBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibrx Biosciences (NASDAQ:INBX)
Historical Stock Chart
From Jul 2023 to Jul 2024